Financials data is unavailable for this security.
View more
Year on year Royalty Pharma PLC grew revenues 5.24% from 2.24bn to 2.35bn while net income improved 2,549.50% from 42.83m to 1.13bn.
Gross margin | -- |
---|---|
Net profit margin | 46.02% |
Operating margin | 42.91% |
Return on assets | 5.92% |
---|---|
Return on equity | 10.55% |
Return on investment | 7.77% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Royalty Pharma PLC fell by 1.23bn. However, the company earned 2.99bn from its operations for a Cash Flow Margin of 126.89%. In addition the company used 2.07bn on investing activities and also paid 2.15bn in financing cash flows.
Cash flow per share | 1.40 |
---|---|
Price/Cash flow per share | 19.94 |
Book value per share | 14.42 |
---|---|
Tangible book value per share | 14.42 |
More ▼
Balance sheet in USDView more
Current ratio | 9.35 |
---|---|
Quick ratio | -- |
Total debt/total equity | 1.17 |
---|---|
Total debt/total capital | 0.4381 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 1.42% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 54.64% |
EPS growth(5 years) | 1.83 |
---|---|
EPS (TTM) vs TTM 1 year ago | 167.73 |
More ▼